Long-term Debt - Additional Information (Details) - USD ($) |
3 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|
Feb. 13, 2025 |
Oct. 18, 2023 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Dec. 31, 2024 |
Nov. 07, 2024 |
|
| Line of Credit Facility [Line Items] | |||||||||
| Debt instrument unpaid principal balance | $ 40,000,000 | ||||||||
| Debt instrument outstanding amount addition (reduction) to liability | 1,500,000 | $ 2,200,000 | |||||||
| Credit Agreement | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Debt aggregate amount | $ 50,000,000 | ||||||||
| Revenue covenants amount | $ 67,500,000 | ||||||||
| OrbiMed | Credit Agreement | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Revenue covenants amount | $ 115,000,000 | $ 73,000,000 | |||||||
| OrbiMed | Credit Agreement | Scenario Forecast | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Revenue covenants amount | $ 103,000,000 | $ 92,000,000 | $ 84,000,000 | $ 78,000,000 | |||||
| Senior Secured Credit Facility | OrbiMed | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Credit agreement term | 5 years | ||||||||
| Line of credit facility description | On October 18, 2023 (the “Closing Date”) the Company entered into a credit agreement, by and between the Company, as borrower, and an affiliate of OrbiMed Advisors, LLC (the “Lender”) as the lender and administrative agent (the “Credit Agreement”). The Credit Agreement provides for a five-year senior secured credit facility in an aggregate principal amount of up to $90.0 million, of which (i) $40.0 million was made available on the Closing Date (the “Initial Commitment Amount”), (ii) $25.0 million will be made available, at the Company’s discretion, on or prior to December 31, 2024, subject to certain net revenue requirements, and (iii) $25.0 million will be made available, at the Company’s discretion, on or prior to June 30, 2025, subject to certain net revenue covenants (the “Loan Facility”). The maturity date of the Credit Agreement is October 18, 2028 (“Maturity Date”). On the Closing date, the Company closed on the Initial Commitment Amount, less certain fees and expenses payable to or on behalf of the Lender. The Company received net proceeds of $38.8 million upon closing after deducting the Lender's transaction costs in connection with the Loan Facility. On November 7, 2024, the Lender and the Company mutually agreed to a third amendment (the “Third Amendment”) to the Credit Agreement. Under the terms of the Third Amendment and subject to the payment by the Company of a consent fee to the Lender, the Company and the Lender mutually agreed to (1) terminate the two additional tranches of available debt in the aggregate amount of $50.0 million and (2) remove the trailing 12-month revenue covenant for the fourth quarter of 2024, which was set at $67.5 million. On February 13, 2025, the Lender and the Company mutually agreed to a fourth amendment (the “Fourth Amendment”) to the Credit Agreement. Under the terms of the Fourth Amendment, the Company and the Lender mutually agreed to amend the trailing 12-month revenue covenant to $73.0 million for the quarter ending March 31, 2025, to $78.0 million for the quarter ending June 30, 2025, to $84.0 million for the quarter ending September 30, 2025, to $92.0 million for the quarter ending December 31, 2025 and to $103.0 million for the quarter ending March 31, 2026, and Lender received the Penny Warrants. The $115.0 million revenue covenant for all subsequent quarters through the date of debt maturity remains in effect. On March 31, 2025, the Company received a waiver related to the trailing 12-month revenue covenant for the first quarter of 2025, and paid the Lender a fee. All revenue covenants for subsequent quarters remain in effect. | ||||||||
| Aggregate principal amount | $ 90,000,000 | ||||||||
| Current borrowing capacity | $ 40,000,000 | ||||||||
| Maturity date | Oct. 18, 2028 | ||||||||
| Proceeds from debt, net of issuance costs | $ 38,800,000 | ||||||||
| Line of credit facility, exit fee percentage | 3.00% | ||||||||
| Quarterly installment percentage of outstanding principal amount | 5.00% | ||||||||
| Repayments on outstanding debt | $ 0 | ||||||||
| Debt Instrument, fixed percentage | 4.00% | 12.32% | |||||||
| Debt Instrument, variable percentage | 8.00% | ||||||||
| Warrants, exercise price | $ 10.9847 | ||||||||
| Warrants, expiration term | 10 years | 10 years | |||||||
| Senior Secured Credit Facility | OrbiMed | Maximum | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Line of credit facility, repayment premium percentage | 3.00% | ||||||||
| Senior Secured Credit Facility | OrbiMed | Minimum | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Line of credit facility, repayment premium percentage | 0.00% | ||||||||
| Unrestricted cash and cash equivalents | $ 10,000,000 | ||||||||
| Senior Secured Credit Facility | OrbiMed | First Tranche On or Prior to December 31, 2024 | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Remaining borrowing capacity | 25,000,000 | ||||||||
| Senior Secured Credit Facility | OrbiMed | Second Tranche On or Prior to June 30, 2025 | |||||||||
| Line of Credit Facility [Line Items] | |||||||||
| Remaining borrowing capacity | $ 25,000,000 | ||||||||